Tag: ankylosing spondylitis; Bechterew
Dermatology Risks Are Likely Different for JAK Inhibitors
NEW ORLEANS — All but one Janus kinase (JAK) inhibitor with dermatologic indications carries a black box...
Retention High With Biosimilar-to-Biosimilar Switch for Arthritis
PHILADELPHIA — When patients with inflammatory rheumatic diseases were switched from one biosimilar agent to another, treatment retention...
Hospitalists Can Get Help for Rheumatology Cases
SAN FRANCISCO — Few of the hospitalists attending a presentation by rheumatologist Sarah Goglin, MD, at the...
FDA Approves Upadacitinib (Rinvoq) for Sixth Indication
The US Food and Drug Administration (FDA) has approved the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) for...
AS Patients Without Spinal Fusion Are a Distinct Subgroup
Syndesmophytes are not present in a subgroup of patients with ankylosing spondylitis (AS) and sacroiliac (SI) joint...
EMA Issues Positive Opinion on the Safety of Filgotinib
The scientific committee of the European Medicines Agency (EMA) has issued a positive opinion of the type...